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7.72 DDD/1000 inh/day or 39.33%. However the amount of funding spent in this 
group of drugs was decreased for 12,850,895.28€ or 14.18%. This research was 
supported by Provincial Secretariat for Science and Technological Development, 
Autonomous Province of Vojvodina project No 114-451-2458/2011 and by 
Ministry of Science and Technological Development, Republic of Serbia project 
No 41012.  
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A RETROSPECTIVE STUDY ON THE BURDEN OF CYTOMEGALOVIRUS DISEASE 
IN IMMUNOSUPPRESSED PERSONS FOLLOWING TRANSPLANTATION BETWEEN 
2007 AND 2011 IN FRANCE  
Ferchichi S1, Aballea S1, Goryakin Y2, Hakimi Z3, Odeyemi I4, Toumi M5 
1Creativ-Ceutical, Paris, France, 2Creativ Ceutical, London, UK, 3Astellas Pharma Global 
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OBJECTIVES: Following solid organ transplantation (SOT) or hematopoietic stem 
cell transplantation (HSCT), patients are at risk of cytomegalovirus (CMV) 
disease. The impact of CMV disease on mortality, graft rejection, hospitalisation 
costs and on the probability of transplant rejection, failure or Graft versus Host 
Disease (GVHD) and other adverse events was estimated. METHODS: A 
retrospective cohort study of a database of hospitalisations in France (PMSI) from 
2007 to 2011 was conducted. Logistic regression was used to estimate the impact 
of CMV disease during initial hospitalisation on the probability of graft rejection 
and mortality over one year, adjusting for age, gender and comorbidities. The 
impact of CMV disease on costs and on length of stay (LOS) was estimated using 
generalised linear modeling, a correction for endogeneity was performed 
afterwards. RESULTS: Among 20,473 SOT and 18,809 HSCT recipients, CMV 
disease was reported in 9.72% and 6.65% of cases respectively. CMV disease was 
associated with a significant increase in mortality (SOT-patients: odds ratio=1.46, 
p=0.0552; HSCT-patients: OR=4.00, p<.0001). Patients with CMV disease at initial 
hospitalisation were more likely to experience graft rejection, failure or GVHD 
(SOT: OR =1.663, p= 0.0005; HSCT: OR=2.605, p <.0001). CMV was related to higher 
LOS and higher costs at initial stay for both subgroups (SOT: 8.7-days, €4,134, 
p<0.0001; HSCT: 8.75-days, €22,252, p<0.0001). The difference in total 
hospitalisation costs over 2 years between patients with and without CMV was 
€13,159 and €32,691 for SOT and HSCT recipients respectively. CMV disease was 
strongly associated with pneumonia (SOT: OR=3.37; HSCT: OR=3.37) and with 
enteritis (SOT: OR=3.63; HSCT: OR=3.90). CONCLUSIONS: CMV disease is 
associated with substantial increases in probability of graft rejection, mortality, 
length of stay, adverse events and hospitalisation costs in French transplant 
recipients. A limitation of this study is that it was not possible to adjust for the 
intensity of immunosuppressive therapy.  
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OBJECTIVES: Although effective chemotherapy is available, tuberculosis (TB) 
remains a major public health problem worldwide. The current study aimed to 
determine the prevalence of pulmonary TB and multi-drug resistant (MDR) TB in 
Baghdad, Iraq. METHODS: Databases of Thoracic and Respiratory Diseases 
Specialist Center were retrospectively reviewed to determine the prevalence of 
pulmonary TB in Baghdad. This center is the largest center for the diagnosis, 
treatment and recording of all new and previously treated TB cases in Baghdad 
and the other states of Iraq. All newly diagnosed TB patients who registered for 
TB treatment between January 1, 2011 and June 30, 2012 were included in the 
analysis. RESULTS: A total of 2968 TB cases were newly registered in Baghdad 
during the period under review. Of these, 1188 cases were smear positive 
pulmonary TB. The prevalence of smear positive and smear negative pulmonary 
TB in Baghdad were 40.02% (95% CI 34.46%-45.58%) and 16.81% (95% CI 12.56%-
21.06%) respectively. Additionally, 1810 of the newly diagnosed TB cases were 
male and 1158 were female. Baghdad accounted for 25.58% (95% CI 21.61%-
29.55%) of the estimated prevalence of smear positive pulmonary TB of the 
country. Furthermore, 103 laboratory-confirmed MDR-TB of new cases were 
reported in Baghdad during the same period. The estimated prevalence of MDR-
TB among newly diagnosed TB cases was 3.47% (95% CI 1.51%-5.43%). 
CONCLUSIONS: The results of the current study will have a significant 
implication for strengthening the TB control program in the capital Baghdad. In 
addition, actions to expand and plan the appropriate diagnostic and treatment 
services for patients with MDR-TB are warranted.  
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OBJECTIVES: To evaluate advanced liver disease outcomes of Medicare 
beneficiaries diagnosed with chronic hepatitis C virus (HCV). METHODS: This 
study was based on 2005-2010 CMS Fee-for-Service Medicare longitudinal claims 
data which includes 100% of the adjudicated medical claims for all inpatient and 
outpatient institutional providers and a 5% sample of adjudicated patient claims 
from the physician office setting. ICD-9 codes were used to identify patients with 
chronic HCV and advanced liver disease outcomes. Disease prevalence and 
trends over time were examined. RESULTS: In 2010, the prevalence rates of 
advanced liver disease such as non-decompensated liver disease (26.5% versus 
0.4%), decompensated cirrhosis (20.8% versus 1.6%), hepatocellular carcinoma 
(4.3% versus 0.1%), liver transplant (3.6% versus 0.06%), were higher (all 
statistically significant, p<0.0001) in the chronic HCV population than the non-
HCV population. Prevalence rates of complications remained stable across the 
six year period, with the exception of decompensated cirrhosis, the prevalence of 
which increased from 15.0% to 20.8% for chronic HCV patients and 0.6% to 1.6% 
in non-HCV patients. CONCLUSIONS: Evaluation of Medicare beneficiaries 
indicates that chronic HCV patients have a greater prevalence of advanced liver 
disease compared with non-HCV patients. The 6-year prevalence trend of 
decompensated cirrhosis has increased for both chronic HCV patients and non-
HCV patients.  
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OBJECTIVES: To characterize the demographics and comorbidities of US 
Medicare beneficiaries diagnosed with chronic hepatitis C virus (HCV) infection. 
METHODS: This study was based on 2005-2010 CMS Fee-for-Service Medicare 
longitudinal claims data which includes 100% of the adjudicated medical claims 
for all inpatient and outpatient institutional providers and a 5% sample of 
adjudicated patient claims from the physician office setting. ICD-9 codes were 
used to identify patients diagnosed with chronic HCV infection as well as the 
following comorbidities: anxiety, depression, alcohol abuse, HIV, and end stage 
renal disease (ESRD). RESULTS: A total of 368,871 chronic HCV patients were 
identified as having received Medicare benefits between 2005 and 2010. The 
average age of these chronic HCV patients in 2010 was 57.2 (SD=11.7) which is 14 
years younger than the non-HCV Medicare population (average = 71.0, SD=13.0). 
Only 28.4% of chronic HCV patients qualified for Medicare due to age alone (≥65 
years old) versus 82.0% of non-HCV patients. The majority of chronic HCV 
patients (63.4%) qualified for Medicare due to a disability that excludes ESRD, 
while only 16.9% of non-HCV patients met the same criteria. Chronic HCV 
patients exhibited a wide array of health problems. The prevalence rates of 
comorbidities such as anxiety (15.2% vs. 4.8%), depression (26.8% vs. 7.6%), 
alcohol abuse (40.9% vs. 2.1%), HIV (8.1% vs. 0.3%) and ESRD (8.5% versus 1.3%) 
were higher (all statistically significant, p<0.0001) in the chronic HCV population 
than the non-HCV population. CONCLUSIONS: Medicare beneficiaries are often 
generalized as over 65 years of age, but chronic HCV Medicare patients are 
typically younger and qualify for Medicare due to disability. The burden of 
patients with chronic HCV on Medicare is further exacerbated by the high 
prevalence of other costly comorbidities.  
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OBJECTIVES: To evaluate the prevalence of advanced liver disease outcomes 
within a large US database of commercially-insured individuals diagnosed with 
chronic hepatitis C virus (HCV) infection. METHODS: This study was based on 
2007-2011 IMS LifeLink claims data which includes adjudicated health claims 
data for 74 million patients and over 75 commercial health plans. ICD-9 codes 
were used to identify patients with chronic HCV and advanced liver disease 
outcomes. Trends in prevalence of these outcomes over time were also 
examined. RESULTS: In 2011, the prevalence rates of advanced liver disease such 
as non-decompensated liver disease (20.48% vs. 0.10%), decompensated cirrhosis 
(15.11% vs. 0.46%), hepatocellular carcinoma (3.43% vs. 0.03%), liver transplant 
(2.58% vs. 0.01%), were higher (all statistically significant, p<0.0001) in the 
chronic HCV population than the non-HCV population. Five-year prevalence 
trends of complications stayed stable, with the exception of decompensated 
cirrhosis and hepatocellular carcinoma. The prevalence of decompensated 
cirrhosis increased from 11.16% to 15.11% for chronic HCV patients and 0.31% to 
0.46% in non-HCV patients. The prevalence of hepatocellular carcinoma 
increased from 2.3% to 3.43% for chronic HCV patients and 0.02% to 0.03% in 
non-HCV patients. CONCLUSIONS: Evaluation of a large US database of 
commercially-insured individuals indicates that chronic HCV patients have a 
greater prevalence of advanced liver disease compared with non-HCV patients. 
The 5-year prevalence trend of decompensated cirrhosis has increased for both 
chronic HCV patients and non-HCV patients.  
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OBJECTIVES: To characterize the demographics and comorbidities of patients 
diagnosed with chronic hepatitis C virus (HCV) infection reporting claims to a 
large US database of commercially-insured individuals. METHODS: This study 
was based on 2007-2011 IMS LifeLink claims data which includes adjudicated 
health claims data for 74 million patients and over 75 commercial health plans. 
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ICD-9 codes were used to identify patients’ comorbidities and advanced liver 
disease complications. RESULTS: The 5-year prevalence rate (2007-2011) of 
chronic HCV among commercially-insured individuals was 0.187% (95%CI 
0.185%-0.188%). In 2011, a total of 27,843 chronic HCV patients were identified. 
The average age of these chronic HCV patients was 53 years (SD 11). Chronic HCV 
patients exhibited a wide array of health problems. The prevalence rates of 
comorbidities such as anxiety (13.5% versus 4.7%), depression (17.9% versus 
5.2%), alcohol abuse (35.3% versus 1.2%), hypertension (46.2% versus 18.6%), type 
2 diabetes (18.8% versus 6.2%), HIV (2.5% versus 0.1%), and ESRD (2.1% versus 
0.1%) were higher (all statistically significant, p<0.0001) in the chronic HCV 
population than the non-HCV population. Similarly, the 2011 prevalence rates of 
advanced liver disease were higher in the chronic HCV population (all p<0.0001), 
including non-decompensated liver disease (20.5% versus 0.1%), decompensated 
cirrhosis (15.1% versus 0.5%), hepatocellular carcinoma (3.4% versus 0.03%), and 
liver transplant (2.6% versus 0.01%). CONCLUSIONS: Chronic HCV patients have a 
wide array of significant health problems and stages of advanced liver disease 
relative to non-HCV patients.  
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OBJECTIVES: The Internet is an important source of health information and 
Google search engine queries are an increasingly useful source of health data. 
The study objective was to analyze Google search query data about herpes labialis 
(“cold sores”) to determine if information-seeking behavior on the topic 
substantiates anecdotal evidence that herpes labialis outbreaks have cyclical, 
seasonal trends. METHODS: Google Trends provides normalized, scaled indices of 
the volume of Google search engine queries by geographic location and time. 
Using the search terms “cold sore” and “cold sores,” weekly search volume 
indices data for 2004-2012 were downloaded and aggregated into weighted mean 
monthly values in three datasets: (2) Worldwide; (2) USA; and (3) Australia. 
Descriptive statistical analyses and rankings were performed to identify/quantify 
cyclical trends (peaks/troughs) in search volume activity. RESULTS: Plots of 
search volume for herpes labialis information over time reveal striking intra-
annual cyclic patterns—moving from high search volume in fall/winter months 
to low volume in spring/summer months. December was the most frequent 
(67%) high volume search month in the Worldwide and USA analyses; most 
frequently June (67%) and May/June (equally 33%) ranked lowest. In Australia 
(with reversed, southern hemisphere seasons), search volume most frequently 
(50%) peaked in June; February was lowest (63%). Quartile analysis (i.e., “top 3 
months” in search volume frequency) showed November/December/January 
peaking in the Worldwide and USA analyses, while June/July/August 
predominated in Australia. Conversely, May/June/July and June/July/August 
ranked lowest in the Worldwide and USA analyses, respectively; 
February/March/May ranked lowest in Australia. CONCLUSIONS: Analyzing 
Internet search data provides valuable insights into health-related behavior and 
disease epidemiology. Results of this study show that Internet research activity 
about herpes labialis has intra-annual cycles, presumably motivated by actual 
outbreaks of herpes labialis and treatment needs. Results loosely correlate with 
seasons, suggesting connections between herpes labialis outbreaks and changes 
in meteorological/climatological conditions.  
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USE OF AN ELECTRONIC HEALTH RECORD (EHR) DATABASE TO STUDY DRUG 
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OBJECTIVES: Develop a methodology to characterize drug resistance among 
inpatients treated for complicated intra-abdominal infection (cIAI) using a 
hospital-based electronic health record (EHR) database. METHODS: This 
retrospective observational study used qualifying inpatient encounters between 
April 1, 2005 and March 31, 2011 in Cerner Health Facts, a de-identified database 
derived from contributing facility EHRs. cIAI encounters required a primary or 
secondary discharge diagnosis of intra-abdominal infection, a qualifying surgical 
procedure and qualifying culture (defined by source/site description and 
interpretable resistance testing) ≤2-3 days from admission. The resistant group 
needed ≥1 positive culture interpreted as resistant to at least one empiric 
antibiotic class (by Multum) based on 2009 Infectious Disease Society of America 
guidelines. A multilevel or hierarchical mixed-effects model assessed risk factors 
associated with resistance across at least two antibiotic classes. RESULTS: A total 
of 953 patients from 62 hospitals met cIAI criteria; 339 (35.6%) in the resistant 
and 614 (64.4%) in the sensitive group. Mean age was 57 years; 52% were male. 
Health care-associated infection (HAI) risk factors were more common among 
the resistant group (31.6% vs. 16.6%, P<0.001). Among the 339 patients in the 
resistant group, 48% (17% of the study population) had resistance to ≥2 guideline 
antibiotic classes. Antibiotic classes with the most resistance were first-
generation cephalosporins, quinolones and third-generation cephalosporins. 
Total charges, length of stay and in-hospital mortality were all higher in the 
resistant group, but did not reach statistical significance. Risk factors associated 
with resistance across at least two guideline empiric antibiotic classes included 
HAI status, infection at the level of the appendix, blood dyscrasias and atypical 
or metastatic neoplasms. CONCLUSIONS: Resistance to antibiotics 
recommended for empiric treatment of cIAI was common, and among those 
with resistance, nearly half had resistance across ≥2 antibiotic classes. Risk 
factors associated with multi-class resistance included HAI subgroup, 
appendicitis, blood dyscrasias and atypical/advanced cancers.  
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THE IMPACT OF RENAL IMPAIRMENT, INFLAMMATORY BOWEL DISEASE AND 
ADVANCED AGE ON MORTALITY AMONG HOSPITALIZED PATIENTS WITH 
CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA  
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OBJECTIVES: Clostridium difficile-associated diarrhea (CDAD) increases the risk of 
hospital mortality. Factors associated with CDAD recurrence include renal 
impairment (RI), inflammatory bowel disease (IBD) and advanced age (≥65 y). 
These factors may also affect mortality risk; how CDAD modifies their effect on 
mortality is unknown. This cohort study analyzed these effects among 
hospitalized patients with hospital-origin CDAD (HO-CDAD) and community-
origin CDAD (CO-CDAD) vs. non-CDAD controls. METHODS: A retrospective 
analysis (4/2005-6/2011) of the Health Facts database (Cerner Corp., Kansas City, 
MO) identified hospitalized adult patients with a positive C. difficiletoxin collected 
≥48 hours (HO-CDAD) or <48 hours (CO-CDAD) after admission. Generalized 
estimating equation models measured the effects of HO- and CO-CDAD, risk 
factors (RI, IBD, age ≥65), and their interactions on hospital mortality. RESULTS: 
4,505 patients with HO-CDAD, 2,825 with CO-CDAD, and 276,486 controls were 
identified. Unadjusted hospital mortality was 13.0% in HO-CDAD, 10.7% in CO-
CDAD and 2.7% in controls. There was no interaction with Age≥65 and CDAD: the 
odds were approximately doubled regardless of CDAD status. However, the effect 
of RI on mortality in HO-CDAD was 1.35 times higher than in controls 
(interaction odds ratio [OR] =1.35; 95% CI, 1.01-1.79). Considering the interaction 
term, the overall OR of dying with RI and HO-CDAD was 1.48 (95% CI, 1.12-2.00). 
Among controls, IBD had no significant effect on mortality (OR = 0.77; 95% CI, 
0.52-1.14). The interaction term for CO-CDAD and IBD was 3.05 (95% CI, 1.20-
7.79), for an overall OR for IBD with CO-CDAD = 2.36 (95% CI, 1.08-5.14). 
CONCLUSIONS: The effect of RI and IBD on mortality varies by CDAD status. RI 
and IBD have a synergistic (multiplicative instead of additive) effect with CDAD 
on mortality; if patients develop CDAD, their risk of dying greatly increases 
versus controls.  
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NON-AIDS RELATED DEATHS, AND MORTALITY REMAINS 
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OBJECTIVES: In the HAART era, timely identification and treatment of non-AIDS 
morbidities can enhance survival. Awareness of disparities in rates and causes of 
death can inform public health strategies. METHODS: Patients studied had ≥2 
visits to any of 10 HIV clinics during 1996-2009. Death rates and causes were 
stratified by age, race, sex, health care payer and calendar period; trends were 
compared using Poisson regression. RESULTS: Among 8519 patients there were 
993 deaths, 430 from AIDS, 469 from non-AIDS and 94 with unknown causes. 
Overall death rates per 100 person-years of follow-up declined during 1996-2000, 
2001-2004, and 2005-2009 from 3.85 to 2.12 to 1.33, respectively (p<0.01 for trend) 
as did AIDS death rates (1.96, 0.91, 0.33; p<0.01 for trend) and non-AIDS death 
rates (1.55, 1.09, 0.78; p<0.01 for trend). Approximately one-third (31%) of 
mortality declines during 2005-2009 were from non-AIDS death reductions and 
65% from AIDS death reductions; non-AIDS death rates remained higher than 
AIDS deaths among patients <45 (0.5 vs. 0.3, p<0.01) but not for patients ≥45 
years. Overall 2005-2009 death rates were higher among blacks than non-blacks 
(2.03 vs. 1.01, p<0.01) and among persons with public health care payers (PUB) 
than non-public payers ([nPUB], 2.66 vs. 0.60, p<0.01). During 2005-2009, non-
AIDS deaths accounted for 64.7% of deaths among blacks and 61.1% among PUB. 
More than 88% of patients received HAART during 2005-2009 in all subgroups; 
rates differed by race (85.6% among blacks, 90.0% among non-blacks, p<0.01) but 
not by payer (88.2% among PUB, 88.8% among nPUB; p = 0.57). CONCLUSIONS: In 
the HOPS, continued mortality declines resulted from decreases in non-AIDS and 
AIDS-related deaths. Excess mortality persisted among blacks and the publicly 
insured, with the majority of deaths from non-AIDS causes, suggesting that 
improved detection and management of chronic non-AIDS diseases are needed 
to achieve further mortality reductions.  
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OBJECTIVES: To estimate the budget impact of changing the market shares of 
liposomal amphotericin B (L-AmB) and amphotericin B lipid complex (ABLC) for 
the treatment of invasive fungal infections (IFIs) in a US hospital. METHODS: An 
Excel-based budget impact model was developed to estimate the costs 
associated with using L-AmB and ABLC for treating adult patients with 
